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ABSTRACT
The posttranscriptional regulatory element (PRE) is
considered to enhance hepatitis B virus (HBV) gene
expressionbyfacilitatingthenuclearexportofintron-
less viral subgenomic RNAs. Its role in the RNA
metabolism of the viral pregenomic RNA (pgRNA) is
currently unknown. We identified a positively cis-
acting splicing regulatory element (SRE-1) and pre-
sent two lines of evidence for its functionality.
Firstly, in a heterologous context SRE-1 functionally
substitutes for a retroviral bidirectional exonic splic-
ing enhancer (ESE). As expected, SRE-1 is a splicing
enhancer also in its natural viral sequence context,
since deletion of SRE-1 reduces splicing of pgRNA
in cell culture experiments. Secondly, we show that
stimulation of HBV RNA splicing by the splicing
factor PSF was repressed by the PRE. Analysis of a
variety of PSF mutants indicated that RNA-binding
and protein–protein interaction were required to
enhance splicing. In addition, we show that the PRE
contributedtopgRNAstability,buthaslittleinfluence
on its nuclear export. Herein, we report for the first
time that the PRE harbors splicing stimulating and
inhibitingregulatoryelementscontrollingprocessing
of the viral pregenome. We discuss a model in which
the regulation of pgRNA splicing depends on cellular
factors interacting with the PRE.
INTRODUCTION
RNA metabolism largely depends on the formation of ribonu-
cleoprotein particle arbitrating RNA processing steps like
splicing, nuclear export and the regulation of mRNA stability
[reviewed in (1–3)]. Precise knowledge of human hepatitis B
virus (HBV) gene expression requires the analysis of its RNA
metabolism. This knowledge is supposed to be useful for the
development of novel antiviral strategies based on the dis-
turbance of accurate viral RNA processing. The HBV is a
noncytopathic, hepatotropic virus with a 3.2 kb circular
partial-double stranded DNA genome which serves as tem-
plate for transcription of the pregenomic/precore mRNA and
subgenomic RNAs [reviewed in (4–6)]. Although there are
several promoters, all viral RNAs terminate at a common
polyadenylation signal. HBV is distantly related to retro-
viruses, contains four open reading frames (ORFs)—core
(C), reverse transcriptase-polymerase (P), surface (S) and
X—which are all encoded on the positive strand. Subgenomic
preS and S RNAs encode three viral surface proteins, all
expressed from a single ORF, whereas the small 0.7 kb
RNA encodes the X-protein. In addition to its function as
template for reverse transcription (RT) into genomic minus
strand DNA, the bicistronic pregenomic RNA (pgRNA) serves
as mRNA for translation of the core and P-proteins. The
precore mRNA initiates upstream of the pgRNA and the
precore-region serves as the translation template for synthesis
of hepatitis B e-antigen. The dual function of the pgRNA as
pregenome and mRNA for more than one protein argues for
accurate processing and stability of viral RNAs being of para-
mount importance for the hepadnaviral life cycle.
In contrast to the related duck HBV where splicing is impor-
tant for infection and expression of the large surface protein
(7) constitutive splicing of HBV is not required to produce
viral proteins. However, splice variants of the HBV pgRNA
have been detected in sera and in liver samples of infected
patients as well as from transfected hepatoma cells (8–12),
indicating that there is yet not recognized function of pgRNA
splicing in HBV infection. In addition, it has been shown
recently by RT–PCR analysis that preS/S mRNAs are spliced
utilizing the 50splice site (50ss) at position 458 and the 30splice
site (30ss) at position 1305 (13). Besides a variety of spliced
genomes the major two splice products (SP) of the pgRNA are
referred to as SP1 and SP2 (8,10). SP1 is generated by remov-
ing the intron ﬂanked by the 50ss at position 2448 and 30ss at
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doi:10.1093/nar/gkj440position 489, whereas SP2 is generated by utilizing an alter-
native 50ss at position 2067 but the same 30ss at position 489.
SP1 is easily detectable by northern blotting and runs close to
the S subgenomic RNA (about 2.1 kb) encoding the small
surface protein. Earlier it was documented that about 30%
of the pgRNA was spliced (14), raising the important question
what are the functions of the fusion and aberrant proteins that
are translated from the spliced viral transcripts (15–17). Fur-
thermore, the question has to be addressed how HBV pgRNA
splicing is regulated and limited to warrant expression of
functional HBV proteins.
During a search for cis-regulatory elements within the HBV
genome a genetic element was identiﬁed referred to as post-
transcriptional regulatory element (PRE) (18–20). The PRE
[nt 1217–1582, (21,22)] is located in the untranslated region of
preS/S subgenomic RNAs, but in the polymerase and X-
protein ORF of the pgRNA and X mRNA, respectively and
facilitatedthenucleocytoplasmictransportofunsplicedpreS/S
subgenomic RNAs (18–20). Prediction of potential 50ss and
30ss within the preS/S subgenomic RNAs suggested that the
PRE might also play a role in inhibiting preS/S RNA splicing
(18). The PRE mediates the nuclear export of unspliced viral
RNAs and it was concluded that DPRE-subgenomic RNAs are
retained in the nucleus where they are subsequently degraded
(18–20). The PRE is able to functionally substitute for the
HIV-1 Rev Responsible Element and it was suggested that
aCRM1-dependentnuclearexportpathway(23)exports PRE-
containing transcripts. However, a PRE-dependent increase
in gene expression was not inhibited by Leptomycin B, an
inhibitor of the CRM1-dependent export pathway or by over
expression of DCAN, which competes with nucleoporins
for binding to CRM1 (24–26). Recently, binding of the
polypyrimidine tract-binding (PTB) protein to the 30 end of
the PRE was demonstrated and PTB was suspected to
be involved in PRE-mediated nuclear export of unspliced
subgenomic RNAs (27).
The PRE is located about 750 nt downstream of the 30ss (nt
489)knowntobeutilizedintensivelyinsplicingofpgRNAand
therefore has in this case an exonic position. In comparison to
the HBV PRE (HPRE) the related woodchuck hepatitis virus
PRE (WPRE) is even more potent to posttranscriptionally
facilitate gene expression especially of heterologous trans-
genes. The functional difference between HPRE and WPRE
probably depends on an additional sequence element referred
to as WPREg domain, which is absent in the HPRE (28). In
addition, both PREs contain subelements referred to as PREa
and PREb domains, which are required for full activity
(21,22). Interestingly, WPRE-dependent stimulation of gene
expression could be inhibited partially by Leptomycin B or
over expression of DCAN, indicating that the WPRE utilizes
other and/or additional mechanism than the HPRE to boost
posttranscriptionally gene expression (25). It was suggested
that the WPRE enhances gene expression at different posttran-
scriptional levels like 30 end processing, splicing and export
and that all three subelements are required for full activity
(25,29,30). Similar conclusions were made for the HPRE
(31–33). Hence, comparison of the properties of HPRE and
WPRE reveals signiﬁcant functional, structural as well as
mechanistically similarities but also distinct differences.
The current study was conducted to evaluate the function of
the HPRE in its natural sequence context of the viral pgRNA.
We discovered that the HPRE regulates HBV pgRNA splicing
due to its positively cis-acting splicing regulatory element
(SRE-1). Accordingly, deletion of the SRE-1 reduced splicing
of pgRNA. We show a moderate additional role of the
HPRE in stabilization of the pgRNA, and its dispensability
for nuclear export of pgRNA. Furthermore, we report that the
splicing factor PSF stimulates pgRNA splicing in an HPRE-
dependent manner underscoring the splicing-regulatory func-
tion of the HPRE. Collectively, we report that the HPRE
harbors an exonic splicing enhancer (ESE) required for
pgRNA splicing. We discuss a model in which the HPRE
regulates splicing of viral RNAs.
MATERIALS AND METHODS
Oligonucleotides
Oligonucleotides were synthesized and puriﬁed as described
previously (34). The oligonucleotides are as follows: 183: 50-
ATCCTGCAGGGCTTTAGGCTTTGATCCC; 1813: 50-CA-
ACAGAAATCCAACCTAGAGCTGCT; 1815: 50-TCTTCC-
AGCCTCCCATCAGCGTTTGG; 1954: 50-ATCGAATTCG-
CTTGTTTTGCTCGCAGCAGGTCTGGAGCAAACATTAT-
CGGGACTG; 1955: 50-ATCGAGCTCGGACAACAGAGT-
TATCAGTCCCGATAA; 2068: 50-GATGAATTCTCCATA-
CTGCGGAACTCCTAGCCGCTTGTTTTGCTCGC; 2213:
50-ATCGAATTCGCTCCTCTGCCGATCCATACTGCGGA-
ACT; 2217: 50-TAAGTCTCTCAAGCGGTGGT; 2244: 50-
TAATACGACTCACTATAGGGCCT. The following oligo-
nucleotides were commercially synthesized (Invitrogen):
antisense primer HBV96-AS (50-GAGATTCCCGAGATTG-
AGATCTTCTGC-30; nt 2420–2447); sense primer HBV97-S
(50-TCCTCAACAACCAGCACGGGACC-30; nt 493–515);
antisense primer HBV64-AS (50-CGAAAAGGTTCCACG-
CATG-30; nt 1235–1253); sense primer HBV69-S (50-GCAC-
TTCGCTTCACCTCTGCACG-30; nt 1583–1604); sense pri-
mer HBV63-S (50-GCTTGTTTTGCTCGCAGC-30; nt 1290–
1307); HBV7-T7AS (50-ccatcgattaatacgactcactatagGGTT-
GACATACTTTCCAAT-30, HBV nt 996–979 in upper case
letters); HBV1A (50-TCATCCTCAGGCC-30; HBV nt 3161–
3173 in upper case letters); HBV44-T7AS (50-ccatcgattaatac-
gactcactatagGGTGTAAATAGTGTCTAGTTTGG-30; HBV
nt 2734–2755 upper case letters); HBV43-S (50-TCATCCTC-
AGGCC-30;HBV nt 2021–2041); H2A-AS (50-ggatcctaatacg-
actcactataggGAACATTGAGATTTCAGGC-30,H2Ant829–
847 in upper case letters); H2A-S (50-CAGCAGTGAG-
AATGAACGC-30,H2A nt19–37);GFP-AS(50-ggatcctaatac-
gactcactataggGTCCATGCCGAGAGTGATCCC-30); GFP-S
(50-CCTGGTCGAGCTGGACGGC-30); glycerinaldehyde-
3-phosphate dehydrogenase (GAPDH) intron-AS (50-gg-
actagttaatacgactcactataGGGTGCGGTGGAGATCTG-30);
GAPDH intron-S (50-CAAGGAGAGCTCAAGGTC-30). T7
RNA polymerase promoter sequences are shown in boldface.
Plasmid constructs and mutagenesis
The HBV expression plasmid pCH-9/3091 (kind gift from
H. Schaller ZMBH, Heidelberg) contains a more than full-
length HBV genome (subtype ayw) in which synthesis of the
pgRNA is under control of a cytomegalovirus (CMV) pro-
moter. Different nucleotide deletions were introduced into
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Dr Christoph Seeger, (35)] according to site directed mutage-
nesis method (Stratagene, USA) using proofreading Pwo DNA
Polymerase (Roche, Germany). To introduce the different
nucleotide deletions the following oligonucleotides were
used: for mutant pHBV-DPRE and ptetHBV-DPRE HBV64-
AS and HBV69-S; for mutant pHBV-Dintron and pHBV-
DintronDPRE HBV96AS and HBV97S, for mutant
pHBV-DSRE HBV64-AS and HBV63-S; PCR products
were puriﬁed with the QIAquick PCR puriﬁcation Kit
(Qiagen, Germany), phosphorylated at the 50 end with 10 U
T4 polynucleotide kinase (Roche) subsequently ethanol pre-
cipitated and resuspended in an appropriate volume of H2O.
PCR products were ligated with the Rapid DNA Ligation Kit
(Roche)following themanufacturer’sinstructions. Finally,the
ligated DNA was digested with 10 U DpnI (New England
Biolabs, USA) for 1 h at 37 C with appropriate buffers, trans-
formed into Escherichia coli strain DH5a. Correct mutagene-
sis was conﬁrmed by sequencing using the Taq-cycle
sequencing protocol with IRD-800 labeled primers (MWG
Biotech, Ebersberg, Germany) and a Licor automated
sequencing device (MWG Biotech). Cloning of the HIV-1
subgenomic env expression vectors SV-env/GAR and SV-
env/HIV#18 (used as a control) have been described recently
(36). The bidirectional SF2/ASF- and SRp40-dependent splic-
ing enhancer regulates human immunodeﬁciency virus type
1 rev, env, vpu and nef gene expression (36). For the construc-
tion of SV-env/SRE-3 (HBV nt 1290–1350) the GAR ESE
ﬂanked by an EcoRI and SacI restriction site was substituted
for the EcoRI–SacI adaptor #1954/#1955. For SV-env/SRE-2
(HBV nt 1267–1350) the GAR ESE was substituted with a
PCR ampliﬁed fragment using primer pair #2068/#183 and
SV-env/SRE-2 as template. For SV-env/SRE-1 (HBV nt
1254–1350) the GAR ESE was substituted with a PCR ampli-
ﬁed fragment using primer pair #2213/#183 and SV-env/
SRE-2 as template. Cloning of pT7cytCoxII used as a
probe to detect human mitochondrial cytochrome c oxidase
II (GenBank accession no. NC 001807) has been described
previously (37). All sequences either inserted by oligonu-
cleotide adaptors or PCR were conﬁrmed by DNA sequencing.
Cell culture and transfection procedure
Huh-7 human hepatoma cells or HeLa-T4
+ cells (38) were
grown as monolayers in DMEM supplemented with 10%
fetal calf serum (FCS). All plasmids used for transfection
were puriﬁed by ion exchange chromatography using the
Maxiprep kit (Qiagen). Transfection was performed using
FuGENE  6 Transfection Reagent (Roche) according to
the manufacturer’s protocol.
In vitro transcription for northern blot analysis
Plasmid pCH-9/3091 was used for the production of DNA
templates for the generation of HBV antisense transcripts
(probe 1 and probe 2, Figure 1A). The following two primers
were used to generate the template for probe 1 by PCR: the
antisense primer HBV7-T7AS and the sense primer HBV1A
and for probe 2 the antisense primer HBV44-T7AS and the
sense primer HBV43-S. cytochrome c oxidase II-speciﬁc
antisense RNA-probe was generated by in vitro transcription
with T7 RNA polymerase (Promega, USA) using the EcoRI
linearized plasmid pT7cytCoxII (37). Plasmid pWA 175 (con-
taining the Histone H2A/a gene, kindly provided by W. Albig,
Go ¨ttingen, Germany) was used for the production of DNA
templates for the generation of histone 2A antisense tran-
scripts. Two primers were used to generate the template for
the H2A probe by PCR: the antisense primer H2A-AS and the
sense primer H2A-S. Plasmid pEGFP-N1 was used for the
production of DNA templates for the generation of GFP
antisense transcripts. Two primers were used to generate
the template for the GFP probe by PCR: the antisense primer
GFP-AS and the sense primer GFP-S. DNA template used for
the in vitro transcription to generate antisense RNA probes
speciﬁc for the GAPDH intron B was raised by PCR on
genomic DNA using antisense primer GAPDH intron-AS
and the sense primer GAPDH intron-S. PCRs for the genera-
tionoftheinvitro transcriptiontemplateswereperformedwith
the mixture containing 80 pmol of each primer in 1· PCR
buffer, 0.2 mM of GTP, ATP, TTP and CTP, and 2.5 U of Taq
DNA polymerase (Roche). The PCR products were puriﬁed by
size exclusion using Microspin G-25 columns (Amersham
Bioscience, Germany) according to the manufacturer’s pro-
tocol, ethanol precipitated and used as templates for in vitro
transcription. Transcription reactions were carried out with
0.5–1.0 mg linearized plasmid or PCR product in a ﬁnal
volume of 20 ml in transcription buffer (Promega) containing
0.31 mM ATP, CTP, GTP, 0.25 mM UTP and 5.0 mM
[a-
32P]UTP (800 Ci/mmol) (Hartmann Analytic, Germany),
5 mM DTT and 20 U RNasin (Promega). The reaction was
started by addition of 20 U T7 RNA polymerase (Promega).
After incubation for 45 min at 37 C, another 20 U of T7 RNA
polymerase were added, and the reaction was continued for
45 min at 37 C. The reaction was terminated by adding 10 mg
of yeast tRNA and 1 U of DNase I (Promega) and incubated
for 15 min at 37 C. Unincorporated nucleotides were removed
by using Microspin G-25 columns.
Northern blot analysis
Huh-7 cells were harvested for 48 h or as indicated after
transfection. Total RNA was prepared using TriPure Isolation
Reagent (Roche) according to the manufacturer’s protocol.
For preparation of cytosolic RNA transfected Huh-7 cells
were washed twice with ice cold phosphate-buffered saline
(PBS), harvested in lysis buffer [10 mM Tris–HCl (pH 8.0),
10 mM KCl, 10 mM MgCl2 and 0.2% NP40] supplemented
with 200 U of RNasin/1 ml lysis buffer. The slurry was trans-
ferred to 2 ml tubes and placed on ice for 10 min, slurry was
pipetted up and down to support cell lysis and cell lysis was
controlled by light microscopy. Nuclei and cell debris were
pelleted by centrifugation (3 min 1000 g at 4 C) and super-
natants were centrifuged again (3 min 1000 g at 4 C). Final
supernatants were transferred to new 2 ml tubes and cytosolic
RNA was extracted using TriPure Isolation Reagent (Roche)
according to the manufacturer’s protocol. RNA was separated
on a 1.2% agarose–formaldehyde gel. RNA was blotted on to a
nylon membrane (Osmonics, USA) and hybridized with
32P-
labeled in vitro transcribed RNA probes overnight at 68 C. To
standardize transfection efﬁciency and RNA loading, northern
blots were hybridized with
32P-labeled in vitro transcribed
antisense GFP probe and antisense GAPDH or antisense
histone 2A probes, respectively. Blots were exposed to Fuji
Nucleic Acids Research, 2006, Vol. 34, No. 1 355Figure 1. The PREis requiredforHBV pgRNAsplicing.(A) Schematic drawingof pgRNA,the majorsplicedRNAs(SP1and SP2),the subgenomic preS/SRNAs
andthepgRNAmutantsDintron,DintronDPREandDPRE.TheHBVprobestodetectpgRNAandsubgenomicRNAs(probe1),pgRNAandSP1RNAspecies(probe
2)aredepicted.Greybox ¼ PRE;verticaldash,50 splicedonor;*,30 spliceacceptor.(B)DeletionofthePREreducesthelevelsofthemajorspliceproductSP1andof
preS/SmRNA.HuH-7cellswerecotransfectedwitheach1.5mgofplasmidtetHBV-Wild-type(WT)ortetHBV-DPRE(DPRE,deletionofnt1254–1582),0.5mgof
thetransactivatorexpressingplasmidpUHD-TAand0.07mgpEGFP-N1tomonitortransfectionefficiency.Forty-eighthoursthereafterRNAwaspreparedand10mg
totalRNAwasanalyzedbynorthernblotting.ThepgRNAandthesubgenomicHBVRNAs(preSandSRNA)weredetectedusingHBVprobe1.Asecondaliquotof
RNA from the same preparation was loaded on to a second gel and analyzed by northern blotting using HBV probe 2 detecting pgRNA and the major spliced RNA
(SP1). To normalize RNA loading and transfection efficiency the same blots were hybridized with histone H2A (H2A) and GFP mRNA (GFP) specific probes.
M,totalRNApreparedfromuntransfectedcells.(C)DeletionofthePREreducessplicing.Sixindependentexperimentsperformedinduplicateswerequantifiedby
phosphoimaging and HBV RNA levels were normalized against RNA loading and transfection efficiency. The percentage of splicing reflects the ratio between the
signalintensityoftheSP1RNAandthepgRNA.TheHBVwild-typeSP1:pgRNAratiowassetas100%.TheSDisindicated(±SD;n ¼ 6).(D)ThePREcontributes
topgRNAstability.HuH7cellswerecotransfectedwitheach1.5mgofplasmidtetHBV-WT(WT)ortetHBV-DPRE(DPRE),0.5mgofthetransactivatorexpressing
plasmidpUHD-TAand0.07mgpEGFP-N1tomonitortransfectionefficiency.Forty-hoursthereafter,cellswereharvested(timepoint0h)ordoxycyclinewasadded
andcellswereharvestedat6or8hthereafter.RNAwaspreparedand10mgtotalRNAwasanalyzedbynorthernblottingusingHBVprobe2todetectedpgRNA.To
normalize RNA loading and transfection efficiency the same blots were hybridized with a histone H2A (H2A) and a GFP mRNA (GFP) specific probe. Two
independent experiments performed in duplicates were analyzed, quantified by phosphorimaging and HBV RNA levels were normalized against RNA loading and
transfectionefficiency.TheSDs are indicated (±;n ¼ 2).(E) DintronDPRE pgRNAis stablyexpressed. HuH7cells werecotransfected witheach 1.5mg ofplasmid
tetHBV-WT (WT), tetHBV-Dintron (Dintron, deletion of nt 2446–2496), tetHBV-DPRE (DPRE; deletion of nt 1254–1582), tetHBV-DintronDPRE (DintronDPRE,
deletionofnt2446–2496andofnt1254–1582),0.5mgofthetransactivatorexpressingplasmidpUHD-TAand0.07mgpEGFP-N1tomonitortransfectionefficiency.
Forty-eighthoursthereafterRNAwaspreparedand10mgtotalRNAwasanalyzedbynorthernblottingusingHBVprobe2todetectedpgRNA,GFPandH2Aprobes
to confirm transfection efficiency and RNA loading, respectively. C, mock transfection. (F) Cytosolic accumulation of pgRNA does not depend on the PRE. HuH7
cells were cotransfected in duplicates with each 1.5 mg of plasmid tetHBV-WT (WT) or tetHBV-DPRE (DPRE), 0.5 mg of the transactivator expressing plasmid
pUHD-TAand0.07mgpEGFP-N1tomonitortransfectionefficiency.Fortyhoursthereafter,cellswereharvestedandtotalRNA(total)andcytosolicRNA(cyto)was
prepared as described in Materials and Methods. RNAs were analyzed by northern blotting using HBV probe 2 to detected HBV pgRNAs. Contamination of the
cytosolicRNAfractionwithpre-mRNAswasmonitoredbyreprobingthemembranewithaprobedirectedagainstaGAPDHintron(GAPDHintron)andthequalityof
thecytosolicRNApreparationwasmonitoredbydetectionofthecytochromecOxidaseIImRNA.RNAsoftwoindependenttransfectionswereloadedandanalyzed.
One representative northern blot is shown. For quantification, the northern blot membranes were reprobed with a Histone H2A probe (data not shown) and used for
normalizationofRNAloading.Eachtransfectionwasquantifiedindependently,themeanwascalculatedandtheSDisindicated(±,n ¼ 2).(G)Ratiobetweentotal
and cytosolic WT and DPRE pgRNA was calculated and blotted.
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2000 bio-imaging analyzer (Fuji, Japan) and by TINA soft-
ware (Raytest, Germany).
Determination of pregenomic HBV-RNA
half-life using the Tet-Off-System
Huh-7 cells were transfected with 1.5 mg ptetHBV-WT or
ptetHBV-DPRE and 0.5 mg pUHD-TA, expressing tTA, the
tetracycline-controlled transactivator. Synthesis of pgRNA
was blocked by addition of 500 ng/ml doxycycline to the
culture medium 40 h after transfection. Cells were harvested
directly upon addition of doxycycline or 6 and 8 h thereafter.
Total RNA was prepared and analyzed by northern blot
analysis.
RT–PCR assay
Atotalof2.5 · 10
5HeLa-T4
+cellswereseededintowellsofa
6-well plate (Greiner) and grown as monolayers in 2.5 ml
DMEM supplemented with 10% FCS for 24 h. For RT–
PCR, cells were transfected with 1.5 g of the respective
SV-env plasmid and 0.5 mg of pXGH5 (39) to control trans-
fection efﬁciency, and total RNA was isolated after 30 h.
Total RNA was isolated using a modiﬁed guanidinium isoth-
iocyanate protocol (40). Cells were washed twice with 2 ml of
PBS and cell lysis was performed with 500 ml of buffer D [4 M
guanidinium isothiocyanate, 25 mM sodium citrate (pH 7.0),
0.5% N-lauroyl-sarkosine, sodium salt and 0.4% dextran
blue]. The following solutions are added with vortexing in
between: 7.2 ml of 2-mercaptoethanol, 50 ml of 2 M sodium
acetate (pH 4), 500 ml of phenol and 100 ml of a chloroform-
isoamyl alcohol mixture (24:1). After addition of the latter,
the mixture was vigorously shaken for 15 s, placed on ice for
15 min and phases were separated by centrifugation (10 600 g)
for 20 min at 4 C. RNA was precipitated in 1 vol of iso-
propanol overnight. After centrifugation (10 600 g) RNA
was washed twice with 70% ethanol and dissolved in 16 ml
of DMDC-ddH2O. Before RT, 8 ml of RNA samples were
subjected to DNase I digestion using 10 U DNase I
(Roche) with 50 mM Tris (pH 7.5) and 10 mM MgCl2 in a
total volume of 10 ml at room temperature for 1 h. After DNase
I inactivation at 80 C for 10 min, 4.5 ml of the DNase diges-
ted RNA samples were reversed transcribed with 200 U
SuperScript III RNase H-Reverse Transcriptase (Invitrogen)
according to the manufacturer’s protocol using 0.375 mM
oligo(dT)15 (Roche) as primer. PCR was carried out with
1.25 U AmpliTaq (Applied Biosystems) in a total volume
of 50 ml according to the manufacturer’s protocol in a Robo-
cycler Gradient 96 Temperature Cycler (Stratagene, USA).
All primers were used at a ﬁnal concentration of 0.2 mM.
Spliced RNA was detected with primer pair #2244/#2217.
PCR products were separated on 3% Metaphor-agarose gels
and stained with ethidium bromide. For the detection of
hGH mRNA in the RT–PCR assay primer pair #1813/
#1815 was used.
Western blot analysis
A total of 3.0 · 10
5 HeLa-T4
+ cells were seeded into wells of
a 6-well plate (Greiner, Germany) and grown as monolayers
in 2.5 ml DMEM supplemented with 10% FCS for 24 h.
Cells were cotransfected with 1.0 mg of the respective
SV-env plasmid, 1 mg of SVcrev and 1.0 mg pGL3 (Promega)
to monitor transfection efﬁciency. The medium was changed
24 h after transfection and cells were scraped into the medium
24 h later, sedimented at 12 000 g for 14 s, washed in 1 ml PBS
andsuspended in0.5mlPBS.Analiquotof70mlwasanalyzed
for luciferase activity (luciferase assay system, Promega) and
protein concentration (Bradford Protein Assay, Bio-Rad).
The remaining volume of the second PBS washing step was
centrifuged and suspended in 200 ml of SDS–PAGE sample
buffer (41). Each sample was adjusted to equal amounts of
luciferase activity and protein amount by adding extracts of
mock-transfected cells. Samples were heated for 10 min at
95 C and subjected to electrophoresis on a 7% SDS–
polyacrylamide gel and transferred to a PVDF-membrane
(Immobilon  P, pore size 0.45 mm; Millipore) by electroblot-
ting with 500 mA in transfer-buffer (200 mM glycine, 25 mM
Tris base and 20% methanol) for 1 h. Blots were blocked in
PBS with 10% skim milk powder (Oxoid), 0.1% Tween-20,
for 15 min at RT. Protein detection was performed in PBS, 5%
skim milk powder, 0.1% Tween-20, with a monoclonal
mouse-anti-gp120 antibody (87–133/026, 1:5000, kindly pro-
vided by Dade Behring) for 1 h, washed four times with PBS,
incubated in PBS, 10% skim milk powder, 0.1% Tween-20
with a sheep-anti-mouse antibody conjugated with horseradish
peroxidase (HRP) (NA 931, Amersham Bioscience, 1:1000)
for 1 h, washed ﬁve times with PBS, rinsed with water and
visualized by a chemiluminescence detection system (ECL -
system and ECL  hyperﬁlm, Amersham Bioscience; Super
Signal  ultra, Pierce).
RESULTS
The PRE modulates splicing of HBV pgRNA
So far, no information is available on the role of the PRE in
pgRNA processing. To gain insight into the function of the
PRE in the posttranscriptional control of pgRNA metabolism
we deleted the PRE [Figure 1A; DPRE, deletion of nt 1254–
1582, Galibert nomenclature, (42)] within the HBV expression
plasmid pHBV-wild-type (WT) and ptetHBV-WT and moni-
tored splicing, stability and nuclear export of WT and DPRE
pgRNA. To study pgRNA processing DNA of WT or mutant
HBV expression plasmids were transiently transfected into
Huh-7 cells and total RNA was prepared 48 h thereafter.
HBV RNA level, extend of splicing and nuclear export was
analyzed and quantiﬁed as described in Materials and Meth-
ods. As shown in Figure 1B, pgRNA transcribed from plasmid
ptetHBV-DPRE migrates faster than the WT pgRNA (pgRNA,
cf. lanes 2, 3 with 4, 5) due to the deletion of the PRE and was
expressed at slightly reduced levels. Furthermore, as previ-
ously published (18–20) deletion of the PRE abolished expres-
sion of subgenomic preS/S RNAs (Figure 1B, cf. lanes 2, 3
with 4, 5). The major splice product of the pgRNA, referred to
asSP1,was hardly detected (Figure 1B, SP1,cf.lanes7, 8with
9, 10), indicating that deletion of the PRE strongly reduced
pgRNA splicing. Quantiﬁcation of ﬁve independent experi-
ments revealed reduction in pgRNA splicing by about 60%
(Figure 1C). To also visualize whether the expression of the
second prominent pgRNA splice product SP2 was PRE-
dependent, RT–PCR analysis was applied. RT–PCR analysis
also revealed that splice product SP2 was strongly reduced
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Thus, production of SP1 and SP2 spliced pgRNAs depend on
the PRE, indicating that the PRE contains element(s) mediat-
ing the usage of upstream located splice sites.
Since it was observed that DPRE pgRNA levels were
slightly reduced when the PRE was deleted (Figure 1B, cf.
lanes 2, 3 with 4, 5), we next measured the half-life of WT and
DPRE pgRNA. To determine and to compare the half-life of
WT and DPRE pgRNAs, the tetracycline expression system
was used and transfection experiments with ptetHBV-WT or
ptetHBV-DPRE plasmids were accomplished. Huh-7 cells
were transfected either with ptetHBV-WT or ptetHBV-
DPRE plasmid DNA, 40 h thereafter doxycycline was
added to block further transcription and RNA was harvested
6 and 8 h afterwards. The half-life of both, WT and DPRE
pgRNAs were determined in duplicates in two independent
experiments. Wild-type pgRNA comprised a half-life of  5h
[Figure 1D; (35)] whereas the half-life of DPRE-pgRNA was
reducedbyabout 1h(Figure 1D).Weconclude thatthe PREto
some extent contributes to pgRNA stability.
Since the half-life of the pgRNA was slightly reduced in the
absence of the PRE we addressed the question of whether lack
of SP1 RNA detection in the DPRE context might be due to an
altered stability of the spliced SP1-DPRE RNA. We thus
deleted the intron sequence (referred to as Dintron, nt
2446–2496, Figure 1A and E) and created the double mutant
DintronDPRE (Figure 1A and E). Huh-7 cells were transfected
either with ptetHBV-WT, ptetHBV-Dintron, ptetHBV-DPRE
or ptetHBV-DintronDPRE plasmid DNA, 48 h thereafter RNA
was harvested. HBV RNA levels were determined in dupli-
cates in two independent transfections experiments and RNA
was analyzed by northern blotting. The experiment shows that
the DintronDPRE pgRNA is easily detectable although at
somewhat lower levels than Dintron pgRNA, indicating that
the PRE contributes to the stabilization of WT-pgRNA and
SP1 RNA. However, the strong expression of SP1-DPRE
pgRNA excludes the possibility that SP1 RNA is highly unsta-
ble and therefore hardly detectable when the PRE is deleted.
This experiment strongly supports the assumptions that the
PRE is required for HBV RNA splicing to occur.
Originally, the PRE was identiﬁed as a nuclear export ele-
ment of unspliced subgenomic preS/S RNAs. Therefore, we
next asked whether the cytosolic accumulation of pgRNA
depended on the PRE. Hence, Huh-7 cells were transfected
in duplicates with either pHBV-WT or pHBV-DPRE plasmid
DNA and total as well as cytosolic RNAs were prepared 48 h
later. Fractionation was monitored using a probe detecting an
intronic sequence of nuclear pre-GAPDH mRNA which is
present in total RNA but absent in the cytosolic RNA fraction
(Figure 1F, cf. total with cyto) and using a probe detecting the
mitochondrial cytochrome c oxidase II mRNA which is pre-
sent in both, total RNA and the cytosolic RNA fraction
(Figure 1F, cf. total with cyto). The representative northern
blot analysis in Figure 1F shows comparable levels of total and
cytosolic WT and DPRE pgRNAs (Figure 1F). Quantiﬁcation
revealed that the ratio between total and cytosolic WT DPRE
pgRNA was increased compared to the ratio of total to cyto-
solic WT pgRNA, indicating a minor contribution of the PRE
to RNA instability and/or export (Figure 1G). The experiment
also indicates that the nuclear export of unspliced pgRNA
did not largely depend on the PRE. Taken together, the
characterization of the DPRE-pgRNA revealed that the PRE
is important for pgRNA splicing and contributes to pgRNA
stability. However, PRE is not crucial for nuclear export of
viral pgRNA. Data suggest major functional differences of the
PRE in the pgRNA and in the preS/S RNA sequence context.
The PRE covers an ESE
Themostfrequent used30sswithin the pgRNA islocated about
750 nt (nt 489) upstream of the PRE (Figure 1A). We assumed
that the PRE regulates splicing of the pgRNA via one or more
splicing regulatory regions situated within the PRE recruiting
trans-acting factors required for 30ss deﬁnition. The assump-
tion was based on the ﬁnding that RNA levels of the splice
products SP1 and SP2 (using the same 30ss) were drastically
reduced when the PRE was deleted (see above). For this
reason, we considered that the PRE might contain a SRE-1
recognized by SR proteins, a family of splicing regulatory
proteins mostly increasing utilization of either 50ss or 30ss
[reviewed in (43)]. We used the ESEﬁnder program (44) to
predict potential binding sites for the SR proteins SF2/ASF,
SC35, SRp55 and SRp40. Analysis of the PRE sequence
(nt 1253–1583) led to the prediction of numerous putative
SR protein-binding sites within the PRE with one cluster
between nt 1253 and 1290 at its 50 end (Figure 2A).
To analyze whether this cluster covers a functional ESE we
were interested in a heterologous ESE-dependent reporter
system that not only allowed verifying ESE-dependent splic-
ing but also additionally ESE-dependent protection for RNA
degradation. Such a reporter turned out to be the HIV-1 subge-
nomic env-reporter, which we have extensively characterized
during the past (36,45–47). In the presence of the cis-acting
GAR ESE U1 snRNA is recruited to the HIV-1 50ss (SD4) and
protects the RNA from nuclear degradation before splicing. In
the presence of the retroviral HIV-1 Rev protein the protected,
unspliced message is exported into the cytoplasm and is trans-
lated into the envelope glycoprotein. In the absence of Rev U1
snRNA binding initiates spliceosome formation, resulting in
removal of the intron and transportation of the spliced tran-
script into the cytoplasm. Since the HIV-1 envelope glyco-
protein mediates syncytium formation when expressed at the
surface of e.g. HeLa-T4
+ cells, ESE-dependent U1 snRNA
binding can even be visualized microscopically by syncytia.
Using this HIV-1 env reporter we substituted the GAR ESE for
the HBV SRE sequences (SRE-1 nt 1254–1350; SRE-2 nt
1267–1350; SRE-3 nt 1290–1350) and analyzed their activity
to support U1 snRNA binding and to enhance splicing.
Firstly, we co-transfected HeLa-T4
+ cells with the HIV-1
Rev expression plasmid SVcrev and different gp160-reporter
gene constructs either containing a negative control sequence
(Figure 2B, con; carrying a fragment of similar length as the
GAR ESE but avoid of any ESE), or the bidirectional GAR
ESE (Figure 2B, ESE GAR), or HBV SRE-1, SRE-2 or SRE-3
sequence elements (Figure 2B). As demonstrated by western
blot analysis, mock-transfected cells (Figure 2B, lane 6) or
cells transfected with SV-env/HIV#18 (lane 1) did not allow
glycoprotein detection. In contrast, the GAR ESE and the
SRE-1 (Figure 2B, lanes 2 and 5) led to a strong increase
in gp160/gp120 expression. Gp160/gp120 protein expression
was moderately or weakly enhanced with SRE-2 and SRE-3,
respectively (Figure 2B, lanes 3 and 4). From this analysis it is
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sequence covering the cluster of predicted SR protein-
binding sites was included. Shortening of SRE-1 led to a
stepwise reduction in gp160/gp120 protein expression
(SRE-1 > SRE-2 > SRE-3). Data suggest that SRE-1 medi-
ates efﬁciently U1 RNA recruitment to the HIV-1 50ss. The
functionality of SRE-1 was further shown by its ability to
induce syncytium formation in HeLa-T4
+ cells (data not
shown). Thus, results imply that the predicted cluster of SR
protein-binding sites at the 50 end of the SRE-1 acts as an ESE.
Next, the same experiment was repeated in the absence of
HIV-1 Rev in order to monitor ESE-dependent splicing. Again
GAR ESE and the SRE-1 strongly induced splicing whereas
SRE-2 and SRE-3 were less efﬁcient (Figure 2C, cf. lanes 3, 6
with 4, 5). The result is in line with the western blot analysis
and syncytium formation assay emphasizing that the predicted
SR cluster at the 50 end of the SRE-1 acts like an ESE even in a
heterologous sequence context.
To investigate whether deletion of only the predicted cluster
of SR protein-binding sites (Figure 2A; DSRE; deletion of nt
1254–1289) affects pgRNA splicing transfection experiments
were performed with pHBV-WT, pHBV-DPRE or pHBV-
DSRE plasmid DNA and the ratio between SP1 and
pgRNA was analyzed by northern blotting. Quantiﬁcation
of three independent experiments revealed a reduction in
splicing by about 60% when the PRE (Figure 2D, DPRE)
and by about 30% when only the cluster of potential SR
protein-binding sites were deleted (Figure 2D, DSRE). The
result supports the assumption that deletion of a splicing
enhancer should decrease splicing efﬁciency. However, this
result also demonstrates that the predicted cluster of SR
protein-binding sites was not the only determinant for splicing
regulation of pgRNA indicating that additional cis-acting ele-
ments in the PRE might be involved in splicing regulation.
Such additional elements could either act positively in sup-
porting SRE-1activity but also in counteracting SRE-1, so that
Figure 2. ThePREcontainsasplicingenhancerreferredto asSRE-1.(A) Predictionofa clusterofSRprotein-bindingsitesatthe50 endofthePRE.TheESEfinder
program (44) predicts potential binding sites for SF2/ASF, SC35, SRp55 and SRp40. The PRE sequence (nt 1253–1583) was analyzed by the ESEfinder and to
increasestringencythethresholdwassetto3forallpredictedbindingsites.The50 endofthePRE(nt1253–1350)containingaclusterofpotentialSRprotein-binding
sites is enlarged. SRE-1, SRE-2 and SRE-3 depicts the sequence cloned into the HIV glycoprotein reporter plasmid and analyzed for enhancer activity. DSRE
illustrate a deletion (nt 1254–1289) introduced into the HBV expression plasmid pHBV-DSRE used in Figure 2D. (B–D) The 50 end of the PRE contains a splicing
enhancer. (B) The PRE sequences SRE-1, SRE-2 and SRE-3 were cloned into the HIV glycoprotein reporter plasmid SV-env. HeLa-T4
+ cells were co-transfected
with different HIV glycoprotein reporter plasmids containing no enhancer (con), the HIV GAR ESE (36) or the SRE-1, SRE-2 or SRE-3 sequences. The HIV Rev
proteinwasco-expressed.Proteinextractswereprepared48hlaterandanalyzedbywesternblotting(WB)asdescribedinMaterialsandMethods.Asshownin(B)the
SRE-1 element and the GAR ESE increase strongly gp160 and gp120 expression, whereas SRE-2 and SRE-3 were less efficient. (C) HeLa-T4
+ cells were
cotransfectedwithdifferentHIVglycoproteinreporterplasmidscontainingnoenhancer(con),theHIVGARESE(36)ortheSRE-1,SRE-2orSRE-3sequences.The
HIV Rev protein was not co-expressed. Total RNA was prepared 30 h later and analyzed by RT–PCR as described in Materials and Methods. SRE-1 and the GAR-
ESE strongly stimulate splicing (splice) whereas SRE-2 and SRE-3 were less efficient. The human growth hormone gene (hGH) was used as a loading control. M,
molecular weight marker. (D) HuH-7 cells were cotransfected with each 1.5 mg of plasmid tetHBV-WT (WT), tetHBV-DPRE (DPRE), tetHBV-DSRE (DSRE; nt
1254–1289) and analyzed as described in Figure 1B and Materials and Methods. Three independent experiments performed in duplicates were quantified by
phosphoimaging and HBV RNA levels were normalized against RNA loading and transfection efficiency. The percentage of splicing reflects the ratio between the
signalintensityoftheSP1RNAandthepgRNA.TheHBVwild-typeSP1:pgRNAratiowassetas100%.TheSDisindicated(±;n ¼ 3–6).SRE,splicingregulatory
element; ESE, exonic splicing enhancer; 50ss/30ss, splice donor/splice acceptor site.
Nucleic Acids Research, 2006, Vol. 34, No. 1 359the net outcome of pgRNA splicing is a result of positive and
negative cis-acting SREs-1, similar to the 30ss regulation of
e.g. HIV-1 SA7 (48).
The PTB associated splicing factor PSF-enhances HBV
RNA splicing in a PRE-dependent manner
The PRE-dependent modulation of splicing efﬁciency
observed raised the question of whether a splicing factor
stimulates HBV RNA splicing in a PRE-dependent manner.
To address this question, we chose the PTB associated splicing
factor PSF (49) because the splicing factor PTB is known to
bind to the 30 end of the PRE (27) and thus may recruit PSF to
the PRE. In order to examine the possible PRE-dependent
modulatory role of PSF in pgRNA splicing, Huh-7 cells
were cotransfected with plasmid pHBV-WT and expression
vectors for GFP-PSF-WT or GFP. RNA analysis by northern
blotting revealed a PSF-dependent increase in SP1 RNA level
and a slight increase in HBV pgRNA levels (Figure 3B, cf.
lanes 2, 3 with 4, 5). The quantitative evaluation of the ratio
between SP1 showed GFP-PSF-dependent enhancement of
pgRNA splicing by about 40% (Figure 3C, WT). In contrast,
in cells cotransfected with GFP-PSF-WT and pHBV-DPRE
expression plasmids the ratio between SP1 and DPRE
pgRNA increased to about 110% (Figure 3C, DPRE) if com-
pared to cotransfection with the GFP-expression vector alone
(Figure 3, panels B and C). Since WT pgRNA splicing was
only increased with PSF by about 40% we conclude that the
PRE counteracts PSF-dependent splicing. The ﬁndings sup-
port the view that the HPRE contains one or more SREs-1
and argues for a region within the PRE, which represses
PSF-dependent splicing.
In order to map putative domains of PSF required for stimu-
lation of HBV splicing, expression plasmids encoding GFP-
tagged mutants of PSF (Figure 3A) were cotransfected with
plasmid pSM2. The HBV expression plasmid pSM2 contains
an EcoRI head to tail dimer of an HBV genome and synthesis
ofall viral RNAs are driven by authenticHBV promoters only.
Northern blot analysis of RNA of the transfected cells and
quantiﬁcation of the signals revealed that GFP-PSF-WT
increased pgRNA splicing (Figure 3D and E). In contrast,
none of the PSF mutant proteins enhanced splicing of
pgRNA but rather reduced it slightly (Figure 3E). We con-
clude that the RNA recognition motif 2 (RRM2; D1i n
Figure 3A, D and E) and the N-terminal part of PSF (D4i n
Figure 3A, D and E) of PSF are required to increase pgRNA
splicing. The results support the previous assumption that the
RRM2 is required for RNA-binding and the proline-glutamine
Figure 3. PSF-dependent stimulation of HBV RNA splicing is repressed by the PRE. (A) GFP-PSF expression vectors used in this study (79). WT, wild-type;
pgRNA,pregenomicRNA;SP1,majorsplice;PSF,PTBassociatedsplicingfactor;RRM,RNArecognitionmotif;NLSnuclearlocalizationsignal;RGG,Arginine-
glycine-glycine tripeptide rich region; PQ, proline-glutamine rich domain; P, proline-rich domain; M, non-transfected cells. (B) PSF stimulates HBV splicing in a
PRE-dependentmanner.HuH-7cellswerecotransfectedwitheach1.5mgofplasmidtetHBV-wild-type(WT)ortetHBV-DPRE(DPRE)and1.0mgGFP-PSF-WTor
1.0 mg empty GFP vector and 0.5 mg of the transactivator expressing plasmid pUHD-TA. Forty-eight hours thereafter RNA was prepared and 10 mg total RNA was
analyzed by northern blotting. The pgRNA and the SP1 RNAs were detected using HBV probe 2. To normalize RNA loading and to monitor GFP-PSF or GFP
expressionthesameblotswerehybridizedwithcytochrome coxidaseII[(Cytochrome(C)andGFPmRNA(GFPandPSF)]specificprobes.C,totalRNAprepared
fromuntransfectedcells.Arepresentativeexperimentisshown.(C)QuantificationofPSF-dependentstimulationofWTandDPREpgRNAsplicing.Thepercentage
ofsplicingstimulationreflectstheratiobetweenthesignalintensityoftheSP1RNAandthepgRNA.TheHBVwild-typeSP1:pgRNAratioinpresenceofonlyGFP
was set as 100%, therefore the graph shows the PSF-dependent stimulation of pgRNA splicing. Three independent experiments performed in duplicates were
analyzed and quantified. The SD is indicated (±; n ¼ 3). (D) The RRM2 and the N-terminal region of PSF are required to stimulate HBV RNA splicing. Wild-type
HBV expression plasmids were cotransfected with GFP or with GFP-PSF-WT, GFP-PSF-D1, GFP-PSF-D2, GFP-PSF-D3 or GFP-PSF-D4 expression vectors into
HuH-7 cells. Forty-eight hours later RNA was preparedand analyzed by northern blotting for pgRNA and spliced pgRNA(SP1) using HBV probe 2. Expressionof
GFP and different GFP-PSF plasmids was verified by hybridization with a GFP specific probe. To normalize RNA loading the same blot was hybridized with a
GAPDH specific probe. (E) Quantification reveals that only wild-type GFP-PSF is able to stimulate HBV RNA splicing. The percentage of splicing stimulation
reflects the ratio between the signal intensity of the SP1 RNA and the pgRNA. The HBV wild-type SP1: pgRNA ratio in presence of only GFP was set as 100%,
thereforethegraphshowsthePSF-dependentstimulationofpgRNAsplicing.Threeindependentexperimentsperformedinduplicateswereanalyzedandquantified.
The SD is indicated (±; n ¼ 3).
360 Nucleic Acids Research, 2006, Vol. 34, No. 1rich domain in the N-terminal region represents a protein–
protein interface (49). Therefore, a likely prerequisite of the
splicing modulatory function of PSF in HBV splicing is its
direct interaction with HBV RNA via its RRM2. Furthermore,
thedatasuggestthatPSFrequirestheinteractionwith splicing-
regulatory factors via its N-terminal region to modulate splic-
ing of pgRNA.
DISCUSSION
Splicing licensed bulk mRNAs for nuclear export, whereas a
splicing-independent pathway exports intronless mRNAs. A
variety of viruses requiring the temporal or constitutive
expression of unspliced mRNAs, carrying speciﬁc export ele-
ments to warrant export of unspliced RNAs [for review see
(50–52)]. Even though HBV mRNAs contain a number of
frequently used 50ss and 30ss (8–11,14,16,53), functional
implication of splicing in the viral replication cycle is still
not understood yet. The assumption is of interest since viral
proteins are thought to be encoded only by unspliced RNAs.
To ensure translation of the unspliced mRNAs, utilization of
all splice sites must be tightly controlled. Therefore, it seems
reasonable that HBV RNAs carry cis-acting elements, e.g. the
PRE, that guarantees the export of unspliced viral RNAs and/
or that represses splicing (18,19). However, here we describe
that the PRE consists of distinct modular elements, which
positively and negatively act on 30ss usage of the pgRNA.
The newly identiﬁed SRE-1 is located upstream to the PRE
a and b domain that is required for full nuclear export activity
of the PRE (21,22). Additionally, we show that the SRE-1
could functionally substitute for the bidirectional ESE in a
heterologous context.
The observation that deletion of the cluster of predicted SR
binding sites at the 50 end of the PRE signiﬁcantly reduced
pgRNA splicing, although not as efﬁcient as compared to the
deletion of the whole PRE (Figure 2D), argues for additional
SREs-1 in the PRE. Interestingly, it has been shown that PTB
interacts with the 30 end of the PRE, suggesting that PTB is
involved in the export of unspliced subgenomic RNAs (27).
However, PTB is known to repress splicing by interfering with
splice site deﬁnition (54–61) and therefore might effect
pgRNA splicing by binding to the PRE. In previous PRE
investigations the new identiﬁed SRE-1 might have been over-
looked due to the peculiarity of the widely used HIV-1 Rev-
dependent CAT reporter pDM138 (20,21). In this reporter
construct the bacterial CAT ORF is substituted for intronic
HIV-1 gp120 sequences, which is ﬂanked by the weak HIV-1
30ss SA7 (62). Hence, the unspliced CAT message is exported
to the cytoplasm only if an export element, such as the PRE,
overcomes the nucleocytoplasmic export of the spliced mess-
age (20). As shown by Yen and coworkers (27) mutation of the
predicted PTB binding site 2 within the PRE led to a decrease
in CAT activity. The ﬁnding indicates an impeded export of
the unspliced message and thus supports the hypothesis that
the PRE serves as an export element. However, if PTB binding
represses splicing of pDM138 by binding to the PRE, mutation
of the PTB binding site would strengthen the SRE-1 leading
to efﬁcient utilization of the HIV-1 30ss SA7. Therefore, the
CAT ORF would be removed, the spliced RNA exported
and consequently a reduction in CAT activity determined.
However, pDM138 cytoplasmic RNA levels have been
assessed only by a CAT probe (intronic sequence) and thus
it remains unclear whether the spliced message has increased
within the cytoplasm due to the PTB mutation. Hence, the
PRE might have sequence context dependent functions:
located within the pgRNA, PRE regulates splicing and loca-
ted within the subgenomic RNA, PRE mediates the export of
unspliced RNAs. In addition, factors interacting with the PRE
eventually support both functions, e.g. PTB represses pgRNA
splicing and facilitates the export of unspliced subgenomic
RNAs (27,63).
The SRE-1 is a splicing enhancer located about 750 nt
downstream of the intensively used 30ss. The dsxRE splicing
enhancer has been shown to be active over a comparable far
distance of 500 nt (64). However, RNA loop formation could
bridge the apparent distance to bring the SREs-1 in close
proximity to the 30ss (65). Recently, Loeb and coworkers
(66) have shown for the pgRNA of DHBV that RNA duplex
formation between region A and region B could bridge 1100 nt
to bring the 50 and 30ss in close proximity resulting in sup-
pression of splicing. In addition, it is likely that PTB might be
involved in counteracting splice site selection of the pgRNA
by formation of an RNA loop. Recently, it has been described
that PTB led to exon exclusion by binding to intronic
sequences and subsequent PTB multimerization leading to
RNA loop formation unfavorable for recognition of the looped
exon (54). We envision a model in which PTB binds to the 30
end of the PRE and the polypyrimidine tract of the 30ss form-
ing an RNA loop critical for pgRNA splicing. In such a sce-
nario, PTB would eventually compete for the PTB-associated
splicing factor PSF that strongly stimulates pgRNA splicing
only in the absence of the PRE (Figure 3B and C). PSF spe-
ciﬁcally interacts with the polypyrimidine tract close to the
30ss (49) and probably replaces U2AF
65 during the second
catalytic step of splicing (67). Hence, overexpression of
PSF would change the balance between PTB-dependent splic-
ing inhibition and PSF-dependent splicing stimulation—
further supported by trans-acting factors such as the SRE-
1-binding SR proteins—leading to an increase in splicing as
depictedinFigure3C.Accordingly,deletionofthe PREwould
prevent RNA loop formation, abrogating PTB-mediated
inhibition of splicing and thus explain an increase in PSF-
dependent splicing. Formally, it might also be possible that
overexpression of PSF recruits PTB from the PRE leading to a
loss of inhibition. However, our analysis of GFP-PSF mutants
PSFD1 and PSFD2 (Figure 3D and E) revealed that the RNA
recognition motif2was required, suggesting that PSF interacts
with pgRNAtostimulate splicing.Hence, ifbothPTBandPSF
compete for the polypyrimidine tract at the 30ss, exogenous
PSF would replace PTB and stimulate splicing of pgRNA.
Furthermore, lack of PSF function following deletion of the
N-terminal part including the proline-glutamine rich sequence
suggeststhattheprotein–proteininteractionforsplicingstimu-
lation is essential, too. The regions required for direct inter-
action between PTB and PSF is not mapped yet and because
PSF is part of an even bigger complex, containing p54
nrb, U1,
U2 snRNPs plus a variety of additional proteins (67,68), PTB
and PSF could interact temporarily (69).
In conclusion, we show for the ﬁrst time that the PRE is a
splicing regulatory element containing at least one splicing
enhancer balancing pgRNA splicing. It seems likely that
the PRE functions in a RNA sequence context dependent
Nucleic Acids Research, 2006, Vol. 34, No. 1 361manner: situated in the pgRNA it regulates splicing, present in
subgenomic RNAs it regulates intronless RNA export (18,20)
and placed in heterologous sequence context it affects RNA
processing events (31,32). In the future, it will be challenging
to investigate the fundamental importance of the PRE in the
control of pgRNA splicing and its function in the nuclear
export of subgenomic RNAs during viral infection. The func-
tional modulation of SR proteins (70–76) and there function in
nuclear RNA export (77,78) are important aspects for HBV
RNA processing.
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